CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $446,000 | +143.1% | 100,000 | +161.6% | 0.00% | +200.0% |
Q4 2020 | $183,485 | +61.0% | 38,226 | +95.7% | 0.00% | -50.0% |
Q3 2020 | $114,000 | -5.8% | 19,532 | +9.0% | 0.00% | 0.0% |
Q2 2020 | $121,000 | -74.4% | 17,914 | -75.9% | 0.00% | -66.7% |
Q1 2020 | $472,000 | -83.0% | 74,246 | -72.1% | 0.01% | -71.4% |
Q4 2019 | $2,773,000 | +60.6% | 265,934 | -39.5% | 0.02% | +61.5% |
Q3 2019 | $1,727,000 | +350.9% | 439,507 | +1607.3% | 0.01% | +550.0% |
Q2 2019 | $383,000 | -88.7% | 25,743 | -81.2% | 0.00% | -92.9% |
Q1 2019 | $3,397,000 | -8.5% | 136,900 | -33.7% | 0.03% | -6.7% |
Q4 2018 | $3,711,000 | -5.0% | 206,626 | +55.4% | 0.03% | +15.4% |
Q3 2018 | $3,906,000 | +173.7% | 132,993 | +323.6% | 0.03% | +225.0% |
Q2 2018 | $1,427,000 | +613.5% | 31,393 | +968.9% | 0.01% | +700.0% |
Q4 2017 | $200,000 | -90.3% | 2,937 | -88.3% | 0.00% | -92.9% |
Q3 2017 | $2,060,000 | +17.6% | 25,000 | +33.7% | 0.01% | +16.7% |
Q2 2017 | $1,751,000 | -23.6% | 18,700 | -48.1% | 0.01% | -29.4% |
Q1 2017 | $2,292,000 | -3.5% | 36,000 | -32.7% | 0.02% | +30.8% |
Q4 2016 | $2,376,000 | -44.1% | 53,500 | -54.7% | 0.01% | -38.1% |
Q3 2016 | $4,253,000 | +178.2% | 118,000 | +5.8% | 0.02% | +200.0% |
Q2 2016 | $1,529,000 | -19.1% | 111,512 | +13.3% | 0.01% | -36.4% |
Q1 2016 | $1,890,000 | -53.5% | 98,400 | -15.2% | 0.01% | -52.2% |
Q4 2015 | $4,064,000 | +123.2% | 116,100 | +486.4% | 0.02% | +130.0% |
Q3 2015 | $1,821,000 | -5.5% | 19,800 | -9.7% | 0.01% | 0.0% |
Q2 2015 | $1,927,000 | +29.7% | 21,925 | +9.5% | 0.01% | +25.0% |
Q1 2015 | $1,486,000 | -30.6% | 20,025 | -57.6% | 0.01% | -46.7% |
Q3 2014 | $2,142,000 | +72.5% | 47,228 | +57.4% | 0.02% | +50.0% |
Q2 2014 | $1,242,000 | -76.5% | 30,000 | -60.8% | 0.01% | -80.8% |
Q1 2014 | $5,295,000 | +1.1% | 76,441 | -11.2% | 0.05% | +2.0% |
Q3 2013 | $5,235,000 | – | 86,098 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |